Lectus gets £3 million from the Wellcome

Investment

Lectus Therapeutics Ltd, a drug discovery and development company specialising in ion channel modulators, has been awarded £3 million under the Wellcome Trust’s Seeding Drug Discovery Initiative to identify new classes of selective potassium channel modulator drug candidates for the treatment of multiple sclerosis.

Lectus will use its LEPTICS platform technology to identify drug candidates targeting a novel mechanism of action that is anticipated to address some of the drawbacks associated with existing drugs and those currently under development. The Wellcome Trust retains the option to fund subsequent preclinical and clinical development of compounds identified under the alliance.